Table 4. The significant IPA canonical pathways associated with the common differentially expresses genes in SCLCCs-CD105 cells from primary Caki-2 and metastatic ACHN RCC cell lines.
The scoring method used for selection of canonical pathways was Fisher’s Exact Test. The ration (r) is calculated by the number of genes involved and diving by the total number of genes in that canonical pathway in IPA.
| Ingenuity canonical pathways | -log(p value) | Ratio (r) | Molecules |
|---|---|---|---|
| Leukocyte Extravasation Signaling | 6.34E+00 | 1.66E-01 | CD99,MMP7,ICAM1,PTK2B,MMP15,JAM2,CXCL12,ABL1,MMP13,MAPK13,CLDN6,ITGB3,ROCK2,CLDN4,PRKCE,VCL,ACTG2,CTNNB1,MMP1,ACTA1,ACTN1,TIMP3,PIK3C2A,THY1,ITGB2,MMP23B,ICAM3,RAP1GAP,CDC42,PRKCD,ITGA1,MMP9 |
| ILK Signaling | 4.59E+00 | 1.49E-01 | FLNB,SNAI2,FN1,MYH9,BMP2,ITGB8,ITGB3,PPP2R2C,IRS2,ACTG2,VCL,ITGB4,CTNNB1,ACTA1,ACTN1,DSP,FBLIM1,PIK3C2A,SNAI1,VEGFC,MYL7,ITGB2,CDH1,CDC42,IRS1,TNF,MMP9 |
| Inhibition of Matrix Metalloproteases | 4.05E+00 | 2.63E-01 | TIMP3,MMP7,MMP23B,ADAM12,MMP15,THBS2,ADAM10,MMP13,MMP9,MMP1 |
| Regulation of the Epithelial-Mesenchymal Transition Pathway | 3.71E+00 | 1.37E-01 | FZD10,SNAI2,TGFBR1,FGF2,PARD6G,FGF13,NOTCH2,CTNNB1,HMGA2,WNT5B,NOTCH3,ESRP2,PIK3C2A,EGR1,SNAI1,FGFR2,ZEB1,MET,FZD8,CDH1,CDH2,JAG1,MMP9,FZD7,WNT5A |
| Bladder Cancer Signaling | 3.04E+00 | 1.63E-01 | CXCL8,MMP7,FGF2,SUV39H1,MMP15,ABL1,MMP13,VEGFC,FGF13,CDH1,MMP23B,E2F1,MMP1,MMP9 |
| Gα12/13 Signaling | 2.98E+00 | 1.45E-01 | F2RL2,PIK3C2A,F2R,PTK2B,CDH6,CDH11,MYL7,ROCK2,CDH2,CDH1,LPAR1,LPAR2,CDH3,CDC42,LPAR5,CTNNB1,CDH13 |
| Gα12/13 Signaling | 2.98E+00 | 1.45E-01 | F2RL2,PIK3C2A,F2R,PTK2B,CDH6,CDH11,MYL7,ROCK2,CDH2,CDH1,LPAR1,LPAR2,CDH3,CDC42,LPAR5,CTNNB1,CDH13 |
| TREM1 Signaling | 2.94E+00 | 1.74E-01 | CXCL8,NLRC5,IL18,ICAM1,TLR1,CASP1,LAT2,CD86,IL6,TLR3,TNF,CASP5 |
| Paxillin Signaling | 2.93E+00 | 1.53E-01 | PIK3C2A,PTK2B,MAPK13,ITGB8,ITGB3,ITGB2,ARFIP2,CDC42,ITGA11,ITGA1,ACTG2,VCL,ITGB4,ACTN1,ACTA1 |
| Ovarian Cancer Signaling | 2.88E+00 | 1.38E-01 | FZD10,GJA1,MMP7,PIK3C2A,SUV39H1,PTGS1,ABL1,VEGFC,BCL2,FZD8,EDN1,E2F1,EDNRA,CTNNB1,WNT5B,MMP9,WNT5A,FZD7 |
| Wnt/β-catenin Signaling | 2.40E+00 | 1.20E-01 | FZD10,MMP7,GJA1,TGFBR1,CSNK1D,SOX11,SOX2,CSNK2A2,FZD8,CDH1,CDH2,CDH3,DKK3,PPP2R2C,SFRP1,DKK1,CTNNB1,WNT5B,WNT5A,FZD7 |
| HER-2 Signaling in Breast Cancer | 2.11E+00 | 1.45E-01 | ITGB2,PIK3C2A,CDC42,PRKCD,CDK6,PRKCE,PARD6G,ITGB4,ITGB8,AREG,ITGB3 |
| Basal Cell Carcinoma Signaling | 1.96E+00 | 1.45E-01 | FZD8,FZD10,BMP4,BMP2,BMP7,CTNNB1,WNT5B,FZD7,WNT5A,BMP1 |
| Colorectal Cancer Metastasis Signaling | 1.96E+00 | 1.04E-01 | FZD10,MMP7,TGFBR1,PIK3C2A,ADCY4,MMP15,VEGFC,MMP13,IL6,BIRC5,ADCY9,FZD8,CDH1,MMP23B,TLR1,TLR3,CTNNB1,TNF,PTGER4,WNT5B,MMP9,MMP1,WNT5A,FZD7 |
| Type I Diabetes Mellitus Signaling | 1.80E+00 | 1.23E-01 | SOCS3,MAP3K14,MAPK13,BCL2,TRADD,HLA-DMA,CD86,SOCS2,HLA-F,CASP8,TNF,CPE,TNFRSF11B |
| TGF-β Signaling | 1.69E+00 | 1.26E-01 | BMP4,TGFBR1,CDC42,BMP2,SMAD6,BMP7,MAPK13,SERPINE1,PITX2,PMEPA1,BCL2 |
| HIF1α Signaling | 1.63E+00 | 1.20E-01 | SLC2A5,MMP7,MMP23B,EDN1,PIK3C2A,MMP15,MMP13,VEGFC,MAPK13,TCEB1,MMP9,MMP1 |
| VEGF Signaling | 1.62E+00 | 1.24E-01 | ROCK2,PTK2B,PIK3C2A,VEGFC,VCL,ACTG2,SFN,ACTA1,ACTN1,EIF1AY,BCL2 |
| TNFR1 Signaling | 1.57E+00 | 1.49E-01 | MAP3K14,TRADD,CDC42,TNFAIP3,CASP8,BIRC3,TNF |
| PEDF Signaling | 1.47E+00 | 1.27E-01 | ROCK2,SOD2,GDNF,PIK3C2A,MAPK13,ZEB1,CASP8,TCF7,BCL2 |
| Role of JAK1 and JAK3 in γc Cytokine Signaling | 1.47E+00 | 1.33E-01 | IL7R,SOCS3,PTK2B,PIK3C2A,IRS1,SYK,IRS2,IL7 |
| NF-κB Signaling | 1.42E+00 | 1.01E-01 | MAP3K14,BMP4,TGFBR1,PIK3C2A,BMP2,TNFAIP3,FGFR2,TRADD,CSNK2A2,IL18,TLR1,PELI1,INSR,TLR3,CASP8,TNF,TNFRSF11B |
| PCP pathway | 1.40E+00 | 1.29E-01 | ROCK2,FZD8,FZD10,EFNB1,CTHRC1,WNT5B,FZD7,WNT5A |
| IGF-1 Signaling | 1.38E+00 | 1.13E-01 | SOCS3,IGFBP4,CSNK2A2,IGFBP6,PIK3C2A,IRS1,SOCS2,IGFBP5,IRS2,SFN,IGFBP2 |
| p53 Signaling | 1.35E+00 | 1.12E-01 | MDM4,SNAI2,PIK3C2A,JMY,E2F1,CSNK1D,SFN,CTNNB1,BIRC5,BCL2,TP53I3 |
| Interferon Signaling | 1.22E+00 | 1.47E-01 | IFIT1,OAS1,IFI35,IFITM1,BCL2 |
| Notch Signaling | 1.09E+00 | 1.35E-01 | NOTCH2,NOTCH3,JAG1,DTX2,HEY1 |
| STAT3 Pathway | 1.06E+00 | 1.10E-01 | SOCS3,TGFBR1,CISH,FGFR2,SOCS2,MAPK13,INSR,BCL2 |
| BMP signaling pathway | 1.03E+00 | 1.08E-01 | BMP4,BMP2,SMAD6,GREM1,BMP7,MAPK13,PITX2,BMP1 |
| IL-6 Signaling | 9.42E-01 | 9.48E-02 | COL1A1,CXCL8,SOCS3,MAP3K14,CSNK2A2,IL18,PIK3C2A,MAPK13,IL6,TNF,TNFRSF11B |
| IL-12 Signaling and Production in Macrophages | 9.09E-01 | 9.16E-02 | STAT4,IL18,PIK3C2A,PRKCD,MAF,PRKCE,SERPINA1,MAPK13,IL23A,SAA4,TNF,CLU |
| Glioma Invasiveness Signaling | 8.30E-01 | 1.05E-01 | TIMP3,F2R,PIK3C2A,PLAU,MMP9,ITGB3 |
| RAR Activation | 6.96E-01 | 8.02E-02 | NR2F1,ADCY9,CSNK2A2,DHRS3,ALDH1A1,AKR1C3,PRKCD,ADCY4,BMP2,ALDH1A2,SMAD6,PRKCE,MAPK13,RBP1,MMP1 |
| Ceramide Signaling | 4.07E-01 | 7.50E-02 | PIK3C2A,SPHK1,PPP2R2C,TNF,TNFRSF11B,BCL2 |
| Prostate Cancer Signaling | 4.07E-01 | 7.50E-02 | PIK3C2A,SUV39H1,E2F1,ABL1,CTNNB1,BCL2 |
| Breast Cancer Regulation by Stathmin1 | 3.76E-01 | 6.84E-02 | PPP1R14C,PIK3C2A,ADCY4,PPP1R14A,ROCK2,ARHGEF19,ADCY9,CDC42,PRKCD,E2F1,PRKCE,PPP2R2C,ARHGEF18 |
| mTOR Signaling | 3.20E-01 | 6.59E-02 | RPS4Y1,PIK3C2A,PRKCD,IRS1,RPS23,PRKAA2,PRKCE,VEGFC,RPS4Y2,PPP2R2C,INSR,PRR5L |
| B Cell Receptor Signaling | 2.87E-01 | 6.43E-02 | MAP3K15,MAP3K14,APBB1IP,PTK2B,PIK3C2A,CDC42,SYK,EGR1,ABL1,MAPK13,NFATC4 |